UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): June 21, 2017 (June 15, 2017)
HealthLynked Corp.
(Exact Name of Registrant as Specified in its Charter)
Commission File No.: 000-55768
Nevada | 47-1634127 | |
(State of Incorporation) | (I.R.S. Employer Identification No.) | |
1726 Medical Blvd., Suite 101, Naples, Florida | 34110 | |
(Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s Telephone Number, including area code: (239) 513-9022
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On June 15, 2017 and June 16, 2017, HealthLynked Corp. (the “Company”) entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors for the sale of an aggregate of 416,665 shares of its common stock. The shares were sold at a price of $0.30 per share for gross proceeds of $125,000.
In connection with the sales, the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
On June 16, 2017, the Company borrowed $32,500 from its founder, Chief Executive Officer and Chairman of the Board, Dr. Michael Dent, in the form of an unsecured promissory note (the “Note”). The Note bears interest at a rate of 10% per annum and default interest at a rate of 15% per annum and matures on June 16, 2018. The foregoing summary of the terms of the Note is subject to, and qualified in its entirety by, such document attached hereto as Exhibit 10.1, which is incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
The information provided in response to Item 1.01 of this report is incorporated by reference into this Item 3.02.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description | |
10.1 | Unsecured Promissory Note |
2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HealthLynked Corp. | ||
June 21, 2017 | By: | /s/ George O’Leary |
George O’Leary | ||
Chief Financial Officer |
3